EUS guided RFA for the management of pancreatic and peripancreatic tumor; efficacy and safety evaluatio
- Conditions
- Diseases of the digestive system
- Registration Number
- KCT0002467
- Lead Sponsor
- Asan Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 25
1. Persons who are able to understand clinical trials of Adults under the age of 20 and under 80 years old who are voluntarily agreed to participate in this clinical trial, voluntarily agreeing to sign consent for this clinical trial.
2. Patients who have been diagnosed with tumors of pancreas and pancreatic tumors using biopsy.
3. Estimated expectation period of 6 months or more.
4. Patients who are inoperable and can not be Received radiation therapy due to a lack of immunity.
5. Patients who do not respond to existing anti-cancer drugs and radiation therapy
6. cancer patient is examined by CT or MRI
7. Patients with = 50 % of Karnofsky performance status
8. Patient whose results are normal in the blood coagulation test
9. Female of child bearing age must have negative results in pregnancy examinations..
10. Patients who follow the clinical trial procedure and comply with the visit schedule.
11. Patients should not have physiological, family-oriented, social, or geographical conditions that do not permit medical tracking surveys and compliance with this clinical trial.
1. Patient who can not see images of endoscopic ultrasonography.
2. Patients with an obstruction in the endoscopy path
3. disseminated intravascular coagulation
4. Patients who are taking drugs that can cause bleeding, such as aspirin..
5. Chronic obstructive or restrictive chronic lung disease, including breathing difficulty during recess
6. Other serious diseases or medical conditions.
7. Pregnant women, breastfeeding women, and women of child bearing age who don't use proper contraception.
8. Other medical condition that may impair the ability of patients to participate in clinical trials.
9. Patients with significant neurologic or psychiatric disorder, such as dementia or strokes.
10. Despite the treatment unstable heart disease, a heart attack occurs within six months prior to the clinical trial (Even if a heart attack is diagnosed within six months prior to the clinical trial, a heart condition that remains stable is possible for enroll the study.)
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of changes in the size of pancreatic tumours in CT or MRI
- Secondary Outcome Measures
Name Time Method Evaluation of pain level by treatment using pain assessment tool ;Assessment of complications based on treatment via CT/MRI, blood tests and abnormal reactions.